2022 Externship Programs
In 2022, the Yale Biotech Club launched two externship programs with Allyx Therapeutics and Cellinfinity Bio. The YBC externship programs aim to provide students with short-term, fast-paced opportunities to gain valuable hands-on experience in different careers.
Allyx Therapeutics is a clinical-stage start-up company spun out of Professor Strittmatter’s laboratory at Yale. The goal is to develop disease-modifying therapies for neurodegenerative diseases by treating the underlying cause of synapse loss and dysfunction. Through workshops, literature reviews, and cross-team collaboration, students learned how Allyx can expand into other neurodegenerative indications and build research programs beyond Alzheimer’s disease.
Cellinfinity Bio is revolutionizing cell therapy by developing proprietary, next-generation technologies. The company pipeline consists of clinically engineered T cells, NK cells and other immune cells that have potent activity against multiple malignancies including solid tumors. Through this externship, students learned about company operations and strategy, bioinformatics, and IP landscape analysis.



Meet the Planning Team

Milind Singh,
Program Director
.jpg)
Shengyan Jin,
Program Manager

Zhongyu Yuan,
Program Director
.jpg)
Judy Chen,
Program Manager

Jonathan Dow,
Program director

Yiting Xu,
Program Director
.jpg)